| Psoriasis vulgaris
Skyrizi vs Sorilux
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Skyrizi vs Sorilux with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSorilux has a higher rate of injection site reactions vs Skyrizi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sorilux but not Skyrizi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Skyrizi
Sorilux
At A Glance
SC injection
Every 8-12 weeks
IL-23 antagonist
Topical
Twice daily
Synthetic vitamin D3 analog
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris, Arthritis, Psoriatic 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter.
Crohn Disease Induction: 600 mg IV infusion over at least 1 hour at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Ulcerative Colitis Induction: 1,200 mg IV infusion over at least 2 hours at Week 0, Week 4, and Week 8; maintenance: 180 mg or 360 mg SC at Week 12 and every 8 weeks thereafter.
Psoriasis vulgaris Apply a thin layer twice daily to affected areas and rub in gently and completely; avoid contact with the face and eyes.
Contraindications
- Previous serious hypersensitivity reaction to risankizumab-rzaa or any excipient
- Known hypercalcemia
Adverse Reactions
Most common Upper respiratory infections, headache, fatigue, injection site reactions, tinea infections, arthralgia, pyrexia, rash
Serious Cellulitis, osteomyelitis, sepsis, herpes zoster, pneumonia
Postmarketing Eczema, rash
Most common (>=1%) Application site erythema, application site pain
Postmarketing Application site vesicles
Pharmacology
Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine, inhibiting its interaction with the IL-23 receptor and suppressing the release of pro-inflammatory cytokines and chemokines.
Calcipotriene is a synthetic vitamin D3 analog with similar receptor binding affinity as natural vitamin D3; the exact mechanism contributing to clinical efficacy in psoriasis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Skyrizi
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Sorilux
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (9/12)
UnitedHealthcare
Skyrizi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Sorilux
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Skyrizi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Sorilux
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Crohn's Disease: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Sorilux.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SkyriziView full Skyrizi profile
SoriluxView full Sorilux profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.